HLA-B27 Testing — Body Handbook

Screening · §120

HLA-B27 Testing

HLA-B27 is a blood test that, in the right patient, can cut years off the wait for an inflammatory spine-disease diagnosis — and is close to useless in the wrong one. About one in twelve Northern Europeans carries the allele, but only one or two of those hundred ever develop the disease, so the test earns its place only after a clinical picture that already points at inflammatory back pain. The result is permanent, the draw is cheap, and the consequences cascade through three places: how confident the diagnosis becomes, when treatment can start, and what to tell family.

Test · Once Evidence Moderate Chapter Screening

The test pays off when chronic back pain started before 45, wakes you in the second half of the night, and eases when you move — the inflammatory pattern. It's the wrong test when back pain is mechanical or starts later in life. Used well, it can shorten a diagnostic delay that averages five to ten years. A positive does not mean you have the disease. A negative does not rule it out. Done once, the result is yours for life.

HLA-B27 is one variant of a gene that helps your immune system tell your own cells from intruders. Most carriers go their whole lives without it doing anything to them. In a small subset — roughly one or two in a hundred — the immune system tips into attacking the joints where the spine meets the pelvis, and over years that low-grade attack stiffens the back. Why this tips in some carriers and not others is not fully nailed down. The leading theories converge on a single immune-signalling pathway — the same one the most effective drugs for the disease block — which is why uncertainty about mechanism hasn't held up the treatment story.

The genetics also explain the test's limits. HLA-B27 accounts for around a fifth of the inherited risk of ankylosing spondylitis; other genes (and probably the gut microbiome) account for the rest. That's why some patients with the disease test negative, and why most positives go nowhere Brown 1997 Cortes 2013.

What a positive — or negative — actually tells you

The result's meaning depends entirely on who is being tested. In a 55-year-old with mechanical low back pain that eases with rest, a positive is almost certainly a coincidence — most carriers never get the disease. In a 30-year-old whose back pain started two years ago, wakes them at 4am, and eases when they move, the same positive moves the diagnosis across a threshold.

The negative result is the mirror. In a Northern European patient whose history fits, a negative pulls the likelihood of disease down sharply but not to zero — about one in ten patients with the disease test negative, more so among women, Black patients, and East Asian patients Reveille 2012 Sieper 2017. When the test cannot settle the question, an MRI of the joints where the spine meets the pelvis usually can.

When to order it

The test earns its place when chronic back pain (three months or more) started before age 45 and at least one inflammatory feature is present. Ordering it through or alongside a rheumatologist is the cleanest path — the result is interpreted in the framework of a full picture instead of in isolation.

The test itself is a single blood draw, no fasting, results in a few days. Most labs report only positive or negative — the genetic subtypes that matter for risk (and the few that appear to be protective) are not part of routine clinical reporting Khan 2017. ASAS-EULAR and ACR guidelines treat the result as one input among several; first-line treatment is the same anti-inflammatory drug class either way, but a positive can accelerate access to biologic therapy under classification criteria when MRI is ambiguous Ramiro 2023 Ward 2019.

What the result is not

Two readings dominate the misuse of this test. The first: a positive result is a diagnosis. It is not. Lifetime risk of axial spondyloarthritis given a positive test and no affected relatives is roughly one to two percent — for the typical Northern European carrier, the result changes nothing about how their next ten years go van der Linden 1984 Costantino 2015.

The second: a negative result rules the disease out. It does not. About one in ten patients with confirmed axial spondyloarthritis test negative, and the gap is wider in women and in patients with African, Hispanic, or East Asian ancestry whose disease may not carry the allele at all Reveille 2012 Sieper 2017. The diagnosis lives in the whole picture — history, exam, imaging, and gene test together — not in any single line of the report.

Family — should relatives get tested?

This is the hardest question the test raises, and the place patients push for testing that guidelines don't endorse. The short answer for adults with no symptoms: don't test.

The middle path most rheumatologists take: educate adolescent and young-adult relatives on what inflammatory back pain feels like — the slow onset before 45, the night waking, the relief from movement — and lower the threshold for a rheumatology referral if those symptoms appear. The test belongs in the symptomatic relative's workup, not the well one's.

For symptomatic relatives, the test is no different from any other patient with chronic back pain that started young — same indication, same interpretation, with the elevated pre-test probability of a family history baked into how a positive lands.

Where it goes wrong

The single most common mistake is ordering the test on the wrong patient. Mechanical low back pain that started after 45, eases with rest, and is provoked by movement is not the inflammatory pattern — a positive in that patient is overwhelmingly a coincidence, and the result will sit in the chart misleading every clinician who reads it afterwards. In unselected primary-care populations, the positive predictive value of a positive HLA-B27 for axial spondyloarthritis collapses to a few percent.

The mirror mistake is treating a negative as definitive in a patient whose history fits. A young woman with classic inflammatory back pain and a normal HLA-B27 still has axial spondyloarthritis on her differential — disproportionately, because women are diagnosed years later than men in part for exactly this reason Sykes 2015. MRI of the joints where the spine meets the pelvis is what carries the diagnosis when the gene test does not.

A third trap is treating the result as a treatment switch. First-line therapy is the same anti-inflammatory drug class for both positives and negatives. What HLA-B27 status changes is sometimes the speed of biologic access through classification criteria, not the drug picked Robinson 2021 Ramiro 2023.

What it costs to not test when you should

For someone whose back pain fits the inflammatory pattern, the cost of not testing is years on the clock. The average diagnostic delay in axial spondyloarthritis runs five to ten years from when symptoms start — a decade for some Sykes 2015. The delay isn't an abstract data point. It's the version of you that wakes at 4am with stiff hips for a decade before anyone names the problem. The morning that takes an hour to walk off, every day, while the orthopaedic visits, the disc bulge an MRI turns up and everyone blames, the chiropractic adjustments, and the "it's probably just stress" go nowhere. The flights you start dreading because sitting locks the lower back. The slow accumulation of bone changes that, in the people who go undiagnosed long enough, start to fuse the spine.

Effective treatment exists; the disease in 2026 is one of the rheumatology success stories. The delay is the burden, and the test, in the right patient, is the lever that shortens it.

What it changes when the right patient tests positive

For the patient whose history fits and whose result comes back positive, the payoff is a name for the problem and a clear next step. NSAIDs at full anti-inflammatory dose are the first move; if those don't quiet the inflammation over a few weeks, biologic drugs — the TNF and IL-17 blockers — produce major symptom relief in roughly 40–60% of patients within twelve weeks Sieper 2017 Ramiro 2023.

The week-by-week version: the morning stiffness that used to take an hour to walk off shortens to minutes. The 4am wake breaks first, then the sleep holds through the night. The flights stop being something to dread. Friends and family start asking what changed — that's the social-mirror moment for chronic inflammation lifting. The drugs are not cures; missed doses bring the symptoms back. But the felt difference between treated and untreated axial spondyloarthritis is among the largest gaps modern rheumatology delivers.

The test result itself doesn't expire. Done once, the answer is yours for the rest of your life — useful again decades later if a new eye inflammation or joint problem raises the question of whether they're related.

Related territory

Adjacent topics worth knowing about: inflammatory back pain as a clinical syndrome in its own right; MRI of the sacroiliac joints, which carries the diagnosis when the gene test cannot; the specific biologic drug classes used in axial spondyloarthritis; reactive arthritis, acute anterior uveitis, and IBD-associated arthropathy — all enriched in HLA-B27 carriers and worth flagging if any of them are part of your history.

Related in the handbook

Diagnosis

— This gene flags inflammatory back pain — the kind hiding among people told they just have a bad back.

— Inflammatory back pain (young onset, night waking, eases with movement) is the opposite of the mechanical, MRI-bulge kind — this test sorts it.
— A narrow, clinically-targeted gene test — useful only after the symptom picture points the right way.
— Both are single-gene HLA tests, valid for life — but each only matters in its specific clinical setting.
— Another HLA gene test that's only useful for the right clinical picture — here, celiac.
— Inflammatory bowel disease frequently rides with HLA-B27 spine and joint disease. Gut red flags deserve their own workup.
— Stiffness that eases with movement is normal; stiffness that lasts hours and ignores a mobility routine points here.

Substance + claimed effects

HLA-B27 is a class I major histocompatibility complex allele tested via a single blood draw (PCR or flow cytometry), reported simply as positive or negative. The substance in this entry is the test itself — when to order it, what the result means, and what changes downstream. Claimed effects span three domains the description names: (1) diagnostic confidence for axial spondyloarthritis (axSpA) in patients presenting with chronic back pain <45y, (2) the timing and threshold for initiating biologic therapy, and (3) family screening — whether to test asymptomatic first-degree relatives of HLA-B27-positive probands. Secondary consequences include risk stratification for acute anterior uveitis, reactive arthritis, and IBD-associated arthritis Sheehan 2004, and broader psychological effects of receiving a positive or negative result before a clinical diagnosis is made.

Evidence by addressing question

mechanism

HLA-B27 encodes a class I HLA molecule whose biology is partially understood. It presents peptides to CD8+ T cells, and three non-mutually-exclusive hypotheses explain its disease association: the arthritogenic peptide hypothesis (B27 presents a self or microbial peptide that triggers a cross-reactive T cell response), the misfolding / unfolded protein response hypothesis (B27 heavy chains misfold in the endoplasmic reticulum, drive ER stress, and bias toward IL-23/IL-17 signalling), and the heavy chain dimer hypothesis (free B27 heavy chains form aberrant homodimers on the cell surface that engage KIR3DL2 on Th17 cells) Bowness 2015. None has been definitively proven causal, but all converge on the IL-23/IL-17 axis that the most effective biologic therapies target. Mechanism matters for the entry because it explains the asymmetric link: B27 raises risk substantially (~20× over background) but is neither necessary nor sufficient — about 5% of axSpA patients are B27-negative, and only 1–5% of B27-positive people develop axSpA over a lifetime van der Linden 1984. Heritability of ankylosing spondylitis is ~90%; HLA-B27 contributes ~20–25% of that heritability, with non-MHC loci (ERAP1, IL23R, others) explaining additional risk Brown 1997 Cortes 2013.

evidence

HLA-B27 prevalence in unaffected Caucasian/Northern European populations is 6–8% Reveille 2012 Sheehan 2004. Among patients with ankylosing spondylitis it is 80–95%; among non-radiographic axSpA, 70–85%; among acute anterior uveitis, ~50%; among reactive arthritis, 30–70%; among IBD-associated peripheral arthritis, lower but still enriched Sieper 2017 Stolwijk 2012. The ASAS classification criteria for axial SpA include two arms: an imaging arm (definite sacroiliitis on MRI or X-ray plus ≥1 SpA feature) and a clinical arm (HLA-B27 positive plus ≥2 SpA features) Rudwaleit 2009 Sieper 2009. Stand-alone diagnostic performance in chronic back pain <45y: sensitivity ~85–90%, specificity ~90% in Northern European cohorts; positive likelihood ratio ~9, negative likelihood ratio ~0.1 Rudwaleit 2009. Performance degrades in populations with very low baseline B27 prevalence (East Asian) where specificity is higher but pre-test probability of axSpA differs, and in populations with very high baseline prevalence (Native American Pima, Northern Scandinavian) where specificity drops. Population-level prevalence of axSpA among B27-positive individuals from a French cohort was 0.7% — most B27-positive people never develop disease Costantino 2015.

protocol

Clinical practice: test when chronic back pain (≥3 months) began before age 45 and there is at least one inflammatory back-pain feature — insidious onset, improvement with exercise but not rest, nocturnal pain with morning waking, alternating buttock pain — or another SpA feature (psoriasis, IBD, dactylitis, enthesitis, prior uveitis, family history). The single blood draw costs roughly $50–200 in the US; coverage is routine with rheumatology consultation. The test is binary (positive/negative); clinical labs do not subtype the allele despite the existence of disease-associated subtypes (B*27:05, B*27:02, B*27:04) and apparently neutral or protective subtypes (B*27:06, B*27:09) found mainly in Sardinian and Southeast Asian populations Khan 2017. HLA-B27 is one input to the ASAS classification framework; alone it neither rules in nor rules out disease Sieper 2009. Pre-test counselling matters: the result is permanent and may carry insurance and psychological implications. ASAS-EULAR 2022 management recommendations do not change first-line therapy by B27 status, but B27-positive patients may meet classification thresholds for biologic therapy initiation faster in the absence of MRI-confirmed sacroiliitis Ramiro 2023 Ward 2019.

contraindications

There are no medical contraindications to the blood test itself. The meaningful contraindications are indications-based: do not order in adults without back pain or without a personal or family history of SpA-spectrum disease — the test's positive predictive value collapses outside the inflammatory-back-pain population, and a positive result creates lifelong worry and possible insurance exposure without clinical benefit. Do not use as population screening; ACR/SAA/SPARTAN and ASAS-EULAR guidelines explicitly position B27 as an adjunct, not a screening tool Ward 2019 Ramiro 2023. Asymptomatic family members of affected probands are a contested area — see audience below.

misconceptions

The biggest misconception is that a positive result equals a diagnosis. It does not. The lifetime risk of developing ankylosing spondylitis given B27 positivity and no first-degree affected relative is roughly 1–2%; with a first-degree affected relative it rises to ~10–20% van der Linden 1984 Sieper 2017. The mirror misconception is that a negative result rules out axSpA — sensitivity is ~85–90% in Caucasians and lower in Black, Latin American, and East Asian patients with disease Reveille 2012. A third misconception, common among patients with mechanical back pain who incidentally test positive, is that they are destined to develop disease; the negative predictive value of asymptomatic positivity over a 10-year window is very high.

audience

Family screening is the topic the description calls out and the most contested clinical decision space. The 1984 Dutch cohort found that ~21% of B27-positive first-degree relatives of AS probands had clinical AS, vs. ~1.3% in B27-positive controls drawn from the general population — a ~16-fold enrichment van der Linden 1984. No major guideline recommends routine HLA-B27 testing of asymptomatic relatives, on the grounds that knowing the result does not change surveillance behaviour, treatment cannot be pre-emptive, and false reassurance from a negative test is a risk (axSpA still occurs in B27-negative relatives). Symptomatic relatives with chronic back pain <45y should be tested as any other patient meeting that profile. Counselling for adolescents and young adults with a family history is a reasonable middle path: educate on inflammatory back pain features and threshold for rheumatology referral, without ordering the test pre-emptively. Among ethnic populations: HLA-B27 prevalence is highest in some Native American groups (Pima ~20–50%, Inupiat Eskimo ~25%), 6–8% in Northern European Caucasians, ~2–4% in African American, ~1–4% in East Asian, ~1% in Sub-Saharan African Khan 2017 Reveille 2012. AxSpA prevalence tracks roughly with B27 prevalence but not perfectly — Sardinians have high B27 prevalence and the protective B*27:09 subtype, blunting expected disease rates.

failure-modes

The most common failure mode is ordering the test in low-pre-test-probability patients (chronic mechanical back pain, no inflammatory features, age >45 at onset). Bayes' theorem makes the resulting positive practically uninterpretable — most positives are healthy carriers. The second failure mode is delaying or under-utilising MRI. ASAS criteria's imaging arm exists because MRI of the sacroiliac joints is more specific than B27 alone for active inflammation; over-reliance on B27 can both miss B27-negative disease and over-diagnose B27-positive non-disease Robinson 2021. A third failure mode is interpreting B27 status as treatment-determining. Treatment decisions follow disease activity (BASDAI/ASDAS), response to NSAID trial, and imaging; B27 status modifies prognosis and may accelerate biologic eligibility under classification criteria but does not change the drug class chosen Ramiro 2023 Ward 2019. The diagnostic delay in axSpA averages 5–10 years from symptom onset Sykes 2015 — the failure mode is usually under-recognition, not over-testing, but both occur.

practicalities

Out-of-pocket cost is typically $50–200; in-network cost with insurance often $0–50 after a rheumatology or primary-care referral. Specimen requirement is a single blood draw, no fasting, no special prep. Turnaround is 1–7 days depending on lab. Most clinical labs report a binary result; allele subtyping (distinguishing B*27:05 from B*27:09) is research-grade and not part of routine reporting. Insurance implications: HLA-B27 positivity is not a covered disability or pre-existing condition under US ACA-compliant plans, but it can appear in life-insurance and long-term disability underwriting risk models — relevant for some readers when weighing pre-emptive testing.

stakes

The stakes for a reader with inflammatory back pain features sit on the diagnostic-delay clock. AxSpA can be slowly destructive: chronic inflammation at the sacroiliac joints and spine progresses over years to syndesmophyte formation and, in a subset, bony fusion. Mean diagnostic delay is 5–10 years from symptom onset Sykes 2015; women, B27-negative cases, and those without imaging changes wait the longest. HLA-B27 testing shortens that delay when used appropriately — a positive result in a symptomatic patient with one IBP feature crosses the ASAS clinical-arm threshold and moves the workup into rheumatology range immediately, without waiting for MRI changes. For the family-screening reader, the stakes calculation is different: knowing a result reshapes anxiety but does not change surveillance.

payoff

For the appropriately-tested symptomatic patient, the payoff is diagnostic clarity — and downstream, access to highly effective therapy. TNF and IL-17 inhibitors produce profound symptom relief in axSpA, with 40–60% of patients achieving major response by 12–24 weeks Sieper 2017 Ramiro 2023. The HLA-B27 result is one of several inputs that move the patient from "chronic back pain of uncertain cause" to a named disease with an effective drug class. The result is permanent — done once, settled forever.

out-of-scope

Several adjacent topics: inflammatory back pain itself as a clinical syndrome and the IBP criteria, MRI sacroiliac imaging protocols, the ASAS classification criteria in depth, individual biologic agents and their relative effectiveness, reactive arthritis, acute anterior uveitis, and IBD-related arthropathy. Each warrants its own entry.

The credibility range

Optimist case

HLA-B27 is one of the strongest single-gene-allele associations in autoimmunity. In the appropriate clinical context — chronic back pain in a young adult with at least one inflammatory feature — it is a high-leverage diagnostic input: positive likelihood ratio ~9, classification-criteria gateway, and prognostic information about uveitis and family risk all from a single $100 blood draw. Used as ASAS designed it, the test cuts years off diagnostic delay, particularly for patients without imaging changes (non-radiographic axSpA). The mechanism story has matured: convergence of misfolding, peptide presentation, and KIR3DL2 hypotheses on the IL-23/IL-17 axis lines up with the clinical efficacy of IL-17 inhibitors, supporting the test's biological meaning. The result is permanent, cheap, well-understood, and supports a clear downstream action.

Skeptic case

The test is widely over-ordered. Most positives in unselected primary-care populations are healthy carriers — population PPV is ~1–2%. A positive result causes durable patient anxiety, can appear in insurance underwriting, and rarely changes immediate management when ordered outside the rheumatology pipeline. For family screening of asymptomatic relatives, no major guideline supports routine testing because the result does not change surveillance or treatment, and a negative result can falsely reassure. The diagnostic role is also shrinking in importance as MRI of the SI joints becomes more accessible: the imaging arm of ASAS criteria does not require B27 at all. In ethnically heterogeneous populations, sensitivity is lower and the test misses real disease; in some sub-Saharan and East Asian groups, axSpA exists with little B27 contribution. The classification criteria themselves have been critiqued for over-diagnosing when applied outside research settings Akkoc 2017.

Author's call

HLA-B27 testing is a high-value test in the right setting and a low-value test in the wrong one. Recommendation: test when chronic back pain began before 45 and at least one inflammatory or SpA feature is present, ideally after or alongside a rheumatology referral. Don't test when back pain is mechanical, onset is after 45, or no SpA features are present. Don't test asymptomatic relatives routinely — counsel them on IBP features and threshold for referral instead. Evidence base is strong (decades of cohorts, two major guideline frameworks aligning, mechanistic convergence with treatment biology). Controversy exists at the edges (family screening, application outside research populations, low-prevalence ethnic groups) but the core indication is settled. Article should land confidently on the core indication and explicitly mark the edges.

Stakeholder + incentive map

Rheumatology professional bodies (ASAS, ACR, EULAR, SPARTAN): incentivized to refine criteria and protect against both under- and over-diagnosis; produce the major guidelines Rudwaleit 2009 Ward 2019 Ramiro 2023.
Pharma (biologic manufacturers): commercial interest in earlier diagnosis and expanded biologic eligibility, particularly for nr-axSpA. Some critics argue classification criteria have drifted toward expanded eligibility in step with drug-development timelines Akkoc 2017.
Primary care: over-orders in low-pre-test-probability patients due to limited time for full history, and under-refers symptomatic patients with normal X-rays.
Patient communities: spondylitis patient organisations push for earlier testing and recognition; some advocate for family screening that guidelines do not endorse.
Insurers: reluctance to pay for biologics in nr-axSpA without classification-criteria documentation, which can make B27 status quietly determinative of access in practice.

Population variability

Ethnic prevalence of B27: Northern European 6–8%, North American Native 20–50% in some groups, African American 2–4%, East Asian 1–4%, Sub-Saharan African ~1%, Sardinian ~25% but with protective B*27:09 subtype Khan 2017 Reveille 2012.
Sex: Classical AS historically diagnosed 2–3× more in men, but nr-axSpA is roughly 1:1; diagnostic delay is longer in women, who are more often B27-negative Sieper 2017 Sykes 2015.
Age: Symptom onset almost always before 45; testing in older symptom onset adds little.
Comorbidity: IBD, psoriasis, prior uveitis raise pre-test probability independent of B27.
Family history: First-degree relative with AS or axSpA raises lifetime risk of disease given B27 positivity from ~1–2% to ~10–20% van der Linden 1984.

Knowledge gaps

Allele subtyping (B*27:05 vs B*27:09 vs B*27:06) is not done in clinical practice despite known disease-association differences. Whether this matters in mixed-ancestry populations is unresolved Khan 2017.
The precise causal mechanism of B27 in disease remains unproven — arthritogenic peptide, misfolding/UPR, and heavy-chain-dimer hypotheses each explain part of the data Bowness 2015.
Whether early biologic therapy in B27-positive nr-axSpA changes long-term radiographic outcomes is contested; data are accumulating for TNF and IL-17 inhibitors but follow-up is limited.
The gut microbiome's role in B27-mediated disease is an active area; whether microbiome modulation could shift risk in B27-positive carriers is unknown.
The optimal management of asymptomatic B27-positive first-degree relatives — surveillance interval, MRI thresholds, education vs. testing — has no consensus framework.

Scope vs. brief. The brief named three consequences — diagnostic confidence, treatment initiation, and family screening. All three are covered end to end in the body (evidence + protocol cover diagnostic confidence; protocol + failure-modes cover treatment initiation; audience covers family screening). No silent narrowing.

Category. Filed under screening rather than medical or msk-conditions. The substance is a diagnostic test; screening covers screening and diagnostic-testing entries broadly. msk-conditions would fit axial spondyloarthritis itself, which is a separate-entry candidate (see below). action is test, cadence is once — the result is permanent and lifelong.

Rating difficulties.

Scoring an indirect-effect intervention. HLA-B27 testing doesn't directly improve sleep, mood, or energy — it routes the right patient to treatment that does. Scored 2 on sleep, mood, energy, and health_short_term to honour the real downstream effect, anchored to the mean 5–10y diagnostic delay (Sykes 2015) that appropriate testing shortens. Scored 1 on longevity and focus — real but smaller indirect effects.
Evidence at 4, not 5. Decades of cohorts and two major guideline frameworks endorse the test in IBP workup, but the test's role at the edges (family screening, low-prevalence populations) is genuinely contested; 5 would overstate.
Controversy at 2. Core indication is settled; debate sits at family screening and at classification-criteria drift (Akkoc 2017 critique). Not high enough for 3.

Audience scoping. Left unscoped at the meta level. Inflammatory back pain disproportionately presents before 45 but the test is appropriate across genders and adult age bands when indication holds; over-scoping would shrink reach for the women-late-diagnosed problem the body explicitly flags.

Separate-entry candidates.

Axial spondyloarthritis as a condition entry — overlaps in mechanism and treatment but is a distinct substance worth its own scope.
Inflammatory back pain as a syndrome / self-recognition entry — high-leverage for readers who haven't been told to look for the pattern.
MRI of the sacroiliac joints — the imaging arm of ASAS criteria; the diagnostic counterpart this entry repeatedly points at.
Acute anterior uveitis — the B27-linked extra-articular condition most likely to be the patient's first encounter with the allele.

Future links. When the above entries land, this article's out-of-scope section should cross-link to each.

Excluded deliberately.

Allele subtyping (B*27:05 vs B*27:09 etc.) — mentioned briefly under protocol. Not deepened because routine clinical labs don't report subtype and the reader cannot act on it.
Detailed pharmacology of TNF / IL-17 inhibitors — belongs in the axial spondyloarthritis treatment entry, not here.
Reactive arthritis, IBD-associated arthritis, uveitis subtleties — each warrants its own entry; flagged in out-of-scope.
Insurance / underwriting implications covered briefly in audience callout; not expanded because the rules vary by jurisdiction and would date quickly.

Hard call: stakes vs. fear-mongering. The stakes section uses the lived-experience 4am-wake, hour-of-stiffness anchor rather than the spinal-fusion endpoint, on §5c's "anchor on the typical reader" rule. Spinal fusion is real but the tail of long-untreated disease; leading with it would reframe the typical inflammatory-back-pain reader out of the story.